Johnson & Johnson

  • Understanding The Massive Market Potential of Monoclonal Antibodies

    By Leo Sun - August 19, 2013 | Tickers: ABBV, LLY, JNJ, RHHBY

    Over the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules which mimic naturally produced antibodies, forming the foundation of cutting edge oncology treatments, such as antibody drug conjugates (ADCs), biologics, and immunotherapy, which all aim to reduce or eliminate the use of traditional chemotherapy.

    Monoclonal antibodies, which are administered intravenously, have a wide variety of applications, including cancer cell marking, growth signal blocking, the more »

  • Should You Be Worried That Corporate Earnings Are Slowing Down?

    By Mark Morelli - August 18, 2013 | Tickers: SAM, JNJ, MCD

    Several reports are circulating in the financial media that EPS growth for the S&P 500 member companies is slowing down to a trickle (or even poised for an outright drop) and P/E ratios are getting too high. Some analysts say that by later this year earnings will only grow by single digits.

    Should this concern the average retail investor?

    Not if you invest for the long term and more »

  • This Biotech’s Single Egg Will Never Hatch

    By Leo Sun - August 16, 2013 | Tickers: DNDN, JNJ, MDVN

    Shares of Dendreon (NASDAQ: DNDN) have taken a beating over the past month, falling more than 30% over the past week after sales of its prostate cancer therapy Provenge fell short of analyst estimates. Dendreon’s decline illustrates a classic dilemma in biotech investing -- what happens when a company only has a single egg in its basket, and that egg fails to hatch?

    The single egg cracks

    Dendreon only has more »

  • Is This Healthcare Stock Underrated?

    By Leo Sun - August 16, 2013 | Tickers: ELN, GSK, JNJ, PRGO, TEVA

    Shares of Perrigo Company (NYSE: PRGO), one of the world’s largest healthcare suppliers, slid with the broader market on August 15, after the company reported fourth quarter earnings that topped analyst estimates but missed revenue forecasts. Over the past month, Perrigo has drawn a lot of criticism for its $8.6 billion takeover of Irish pharmaceutical Elan Corporation (NYSE: ELN), which redcued its corporate tax rate by moving its more »

  • An All-In Bet on a Game-Changing Diabetes Treatment

    By Leo Sun - August 14, 2013 | Tickers: JNJ, MNKD, MRK, PFE

    Note: This article has been amended to correct the spelling of Afrezza. Motley Fool apologizes for the error.

    In the biotech industry, there are generally two kinds of companies -- those that have established top and bottom line growth from approved products, and those that have pipelines of experimental treatments with a high potential for growth. Conservative investors favor the former, which include well-known companies like Pfizer (NYSE: PFE), Merck (NYSE: MRKmore »)

  • Is The Market Ripe For a Crash?

    By Bob Ciura - August 13, 2013 | Tickers: KO, JNJ, PG

    The S&P 500 Index is up 19% to start the year--an impressive return that has not been without its share of doubters. The chorus of market pessimists only gets louder as the market climbs the wall of worry, and with less-than-stellar underlying earnings growth, some observers are really starting to get nervous.

    Taking all this into account, there’s just one question left for investors to answer: is the more »

  • 5 Reasons This Stock Can Surpass Its Sector

    By Lee Samaha - August 7, 2013 | Tickers: COV, GE, JNJ

    It’s been a tricky market for medical device companies in 2013, but you wouldn’t know it from Covidien’s (NYSE: COV) share price performance.

    The stock is up nearly 23% this year, even while companies like Johnson & Johnson(NYSE: JNJ) have disclosed lower-than-expected growth in surgical procedures. Moreover, the spinoff of Covidien's pharmaceuticals business (to be called Mallinckrodt) turns it into a pure-play medical device company. Why more »

  • Amgen: Onyx Pharmaceuticals Is Worth A Few Dollars More...

    By Amod Saul - August 7, 2013 | Tickers: AMGN, JNJ, ONXX

    It seems Amgen (NASDAQ: AMGN) has decided that Onyx Pharmaceuticals (NASDAQ: ONXX) is worth a few dollars more than the $120 per share it offered a few weeks ago. News agencies are filled with anonymously sourced reports that Amgen is planning to raise its bid to $130 per share.

    If accepted, the acquisition would give Amgen full rights to Onyx's Kyprolis (carfilzomib), a small molecule injectable proteasome inhibitor approved more »

  • Is This Great Dividend Stock in Danger?

    By Adrian Campos - August 7, 2013 | Tickers: JNJ, PG, UL

    Only behind Johnson & Johnson (NYSE: JNJ) and well above Unilever (NYSE: UL) in my performance chart, Procter & Gamble (NYSE: PG) is among the best performing stocks in its industry. The latest earnings call for its fourth quarter of fiscal 2013 just came out, and it's a good time to analyze the future growth and profitability prospects of Procter & Gamble.

    While the firm has one of the strongest global brands more »

  • GlaxoSmithKline: Victim or Villain in China?

    By Victor Alagbe - August 7, 2013 | Tickers: AZN, GSK, JNJ, SNY

    The last reported record of something British forcing drugs on the Chinese people was during the opium wars of which we should let sleeping dogs lie. However, it appears that GlaxoSmithKline (NYSE: GSK), a British company has been caught in the act forcing drugs on the Chinese people albeit through prescriptions. The story of GSK's bribery scandal in China is no longer news; but I would like to point more »

  • What to Expect From an Investment in 3M

    By joshua kubiak - August 6, 2013 | Tickers: MMM, JNJ, UTX

    In addition to making everything from glue to shampoo, 3M (NYSE: MMM) has a history of making money for its investors.  And that's a trend that is showing no signs of slowing down anytime soon.  Some people tend to tie diversification to stable and sub-par returns, but that is not the case here.  3M is growing at an above average pace and at the same time is maximizing shareholder more »

  • Buy These Leading Pharma Companies

    By Shweta Dubey - August 6, 2013 | Tickers: BMY, JNJ, PFE

    A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018. New patents and improvement in research and development will bolster companies’ portfolios, while a growing population and better access to healthcare will be key factors driving the market size for drugs. Pharmaceutical companies are working hard to capitalize on the growing market. Three such more »

  • How Conglomerates Can Stabilize Your Portfolio

    By Justin Pope - August 5, 2013 | Tickers: MMM, GE, JNJ

    Diversification is an important characteristic of every portfolio. With diversity comes stability. The more diversified you are, the more gains and losses you have balancing things out. The same concept can be applied at the individual stock level.

    When a company's business model spans across multiple markets, it enables that company to endure hardship. If one segment of a business is struggling, sometimes the other segments will thrive, and more »

  • Motley Fool CAPS All Stars & Their 3 Favorite Dow Stocks

    By Josh Kohn-Lindquist - August 2, 2013 | Tickers: MMM, JNJ, PG

    Throughout history, following the crowd, or even a single big name, has proven to be a potentially hazardous way for someone to make their investments. Consider how wrong the crowds were during the ".com" bubble, or even "Tulip Mania" in the 1600's. Likewise, in more recent events, an investor would only have to look as far as William Ackman's bullish stance on J.C. Penney, or his short more »

  • Bill Ackman Is Interested in This Consumer Products Company

    By Jason Bond - August 2, 2013 | Tickers: JNJ, PG, CLX

    Procter & Gamble (NYSE: PG) has been under attack lately. Despite the over $200 billion market cap, the consumer products company has come under activist pressure by hedge fund manager Bill Ackman. With the stock up 20% year to date, should investors join Ackman in investing in Procter & Gamble?

    Fundamentals

    Procter & Gamble is one of the world's leading consumer product companies with some of the world's most famous brands more »

  • 3 Resilient Long-Term Investments

    By Dan Moskowitz - August 2, 2013 | Tickers: JNJ, KMB, PG

    The stock market is acting strange. Never before has there been such strong bull and bear opinions. The answer to who’s correct will be revealed when the Federal Reserve discontinues (not just tapers) monetary stimulus and interest rates increase. Can the economy stand on its own two feet?

    What if you could invest in quality companies that were resilient to bear markets? Fear not, these companies exist. 

    Extraordinary diversification more »

  • Dividend Stocks to Own Forever

    By Reuben Brewer - August 1, 2013 | Tickers: JNJ, MCD, PG

    Long-term income investors shouldn't be traders. That means they should look for great companies with large, lasting businesses, and long histories of returning value to shareholders. Three near 3% yielders that fit the bill today are McDonald's (NYSE: MCD), Procter & Gamble (NYSE: PG), and Johnson & Johnson (NYSE: JNJ).

    Size Matters

    When it comes to companies, size comes with its advantages. It allows for economies of scale, a global more »

  • Biotechs With Prostate Cancer Treatments

    By Terry Chrisomalis - July 31, 2013 | Tickers: DNDN, JNJ, MDVN

    There are many types of biotech companies out there with tremendous value. Today, I will focus on the ones that target prostate cancer. Investors should look at these types of companies as they are starting to make good progress on their research. Another reason is that there is a huge billion dollar opportunity in this sector.

    When I say a billion dollar opportunity, I mean it literally. The sector is more »

  • This Biotech’s Cystic Fibrosis Treatments Could Catapult It To Profitability

    By Leo Sun - July 31, 2013 | Tickers: BMY, GILD, JNJ, VRTX

    Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle cell anemia. More than 30,000 Americans are currently diagnosed with CF, and an average of 1,000 new cases surface annually. One in 3,700 births is believed to have the defective CF gene, and it is estimated that more than more »

  • Is a Huge Share Buyback The Cure For This Healthcare Stock?

    By Bob Ciura - July 31, 2013 | Tickers: ISRG, JNJ, MAKO

    Beleaguered healthcare stock Intuitive Surgical (NASDAQ: ISRG) recently announced a new, massive share repurchase authorization. The buyback couldn’t come at a better time. The stock is reeling after a hugely disappointing quarterly report and widespread fears about the safety of its revolutionary da Vinci surgical robots.

    Should investors take this news seriously? Or is management simply trying to buy itself time until it can sort out its underlying problems more »

  • Page 1 of 29